drugset / Trial / NCT04005690
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
Phase 0
Recruiting
90 enrolled
OHSU Knight Cancer Institute
American Association for Cancer Research · collabCardiff Oncology · collabGenentech, Inc. · collabOregon Health and Science University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2026-06-01
- Completion
- 2028-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | Oral |
| Subject | Cobimetinib | Small molecule | — | Oral |
| Subject | Olaparib | Small molecule | — | Oral |
| Subject | Onvansertib | Small molecule | — | Oral |
| Subject | Saruparib | Small molecule | — | Oral |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |